Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Aug;21(4):e573-603.
doi: 10.3747/co.21.1798.

Bortezomib in multiple myeloma: systematic review and clinical considerations

T C Kouroukis  1 , F G Baldassarre  2 , A E Haynes  2 , K Imrie  3 , D E Reece  4 , M C Cheung  3
Affiliations
Review

Bortezomib in multiple myeloma: systematic review and clinical considerations

T C Kouroukis et al. Curr Oncol. 2014 Aug.

Abstract

We conducted a systematic review to determine the appropriate use of bortezomib alone or in combination with other agents in patients with multiple myeloma (mm). We searched medline, embase, the Cochrane Library, conference proceedings, and the reference lists of included studies. We analyzed randomized controlled trials and systematic reviews if they involved adult mm patients treated with bortezomib and if they reported on survival, disease control, response, quality of life, or adverse effects. Twenty-six unique studies met the inclusion criteria. For patients with previously untreated mm and for candidates for transplantation, we found a statistically significant benefit in time to progression [hazard ratio (hr): 0.48, p < 0.001; and hr: 0.63, p = 0.006, respectively] and a better response with a bortezomib than with a non-bortezomib regimen (p < 0.001). Progression-free survival was longer with bortezomib and thalidomide than with thalidomide alone (p = 0.01). In non-candidates for transplantation, a significant benefit in overall survival was observed with a bortezomib regimen (hr compared with a non-bortezomib regimen: 0.61; p = 0.008), and in transplantation candidates receiving bortezomib, the response rate was improved after induction (p = 0.004) and after a first transplant (p = 0.016). In relapsed or refractory mm, overall survival (p = 0.03), time to progression (hr: 1.82; p = 0.000004), and progression-free survival (hr: 1.69; p = 0.000026) were significantly improved with bortezomib and pegylated liposomal doxorubicin (compared with bortezomib alone), and bortezomib monotherapy was better than dexamethasone alone (hr: 0.77; p = 0.027). Bortezomib combined with thalidomide and dexamethasone was better than either bortezomib monotherapy or thalidomide with dexamethasone (p < 0.001). In previously untreated or in relapsed or refractory mm patients, bortezomib-based therapy has improved disease control and, in some patients, overall survival.

Keywords: Bortezomib; multiple myeloma; proteasome inhibitors; systematic review.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Systematic review on bortezomib for multiple myeloma (mm): study flow chart. ASH = American Society of Hematology; ASCO = American Society of Clinical Oncology; RCT = randomized controlled trial; abs = abstract.
See this image and copyright information in PMC

References

    1. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs. 2009;18:957–71. doi: 10.1517/13543780903002074. - DOI - PMC - PubMed
    1. Health Canada . Approval of Velcade with conditions [letter to health professionals] Ottawa, ON: Health Canada; 2006. [Available online at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/vel...; cited January 5, 2011]
    1. Engelhardt M, Kleber M, Udi J, et al. Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma. 2010;51:1424–43. doi: 10.3109/10428194.2010.487959. - DOI - PubMed
    1. National Comprehensive Cancer Network (nccn) NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma. Fort Washington, PA: NCCN; 2011. Ver. 1.2011. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (free registration required); cited January 5, 2011] - PubMed
    1. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23:1716–30. doi: 10.1038/leu.2009.122. - DOI - PubMed